Ruxolitinib has been launched in China and is suitable for the treatment of hematological diseases such as myelofibrosis and polycythemia vera. It should be used in a standardized manner under the guidance of a doctor.

1. Domestic listing status

(1) Approval status: Lucretinib has been approved for market by the China National Medical Products Administration under the trade name "Jiekewei".

(2) Market launch date: The drug was approved in China in 2017 and can currently be purchased with a prescription in domestic hospitals and regular pharmacies.

Scope of indications 2

(1) Bone marrow fibrosis: used for medium to high risk primary bone marrow fibrosis, secondary bone marrow fibrosis caused by polycythemia vera, etc.

(2) Polycythemia vera: Suitable for patients with polycythemia vera who are resistant or intolerant to hydroxyurea.

3 Medication precautions

(1) Prescription requirement: A prescription must be issued by a hematology specialist, and the dosage must be strictly used according to the instructions.

(2) Adverse reactions: Common hematological toxicities such as anemia and thrombocytopenia require regular monitoring of blood routine.

(3) Drug storage: It should be placed in a dry environment below 30 ℃, and after opening, attention should be paid to moisture and light protection.